What is the price of Bio-Path Holdings, Inc. (BPTH)

The price of Bio-Path Holdings, Inc. (BPTH) is $0.035

What is the market cap of Bio-Path Holdings, Inc. (BPTH)

The market cap of Bio-Path Holdings, Inc. (BPTH) is $326.98K

Bio-Path Holdings, Inc. (BPTH) EPS

Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.

Year	EPS	Change
Not enough data for the provided dates.

Year

EPS

Change

Not enough data for the provided dates.

Company	EPS	EPS Difference	Country
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$13.70	-	BE

Company

EPS

EPS Difference

Country